daNIS-3: This trial is assessing different combinations of treatment with standard care for people with metastatic colorectal cancerAn Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)

Summary

Eligible patients will be randomised into the control or investigation arm(s) of the study. The control arm will include participants treated with standard of care (SOC) anti-cancer therapy (bevacizumab with mFOLFOX6 or FOLFIRI) for the second line treatment of metastatic colorectal cancer. The choice of the chemotherapy medications (mFOLFOX6 or FOLFIRI) will be determined by the Investigator based on prior exposure to oxaliplatin or irinotecan. Each investigational arm will include a combination of an investigational drug and the SOC anti-cancer therapy.